TCT 2022 late-breaking clinical presentations announced
The Cardiovascular Research Foundation (CRF) has announced the 32 late-breaking studies being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 annual meeting at the Boston Convention Center, Sept. 16-19. The conference is the largest gathering of interventional cardiologists in the world.
The meeting includes tracks on coronary percutanenous coronary interventions (PCI), structural heart sessions for with a concentrations in transcatheter aortic valve replacement (TAVR), mitral and tricuspid valve repairs and replacements, left atrial appendage (LAA) occlusion, heart failure, endovascular, cardiac device innovation, live cases and a track for nurses/technologists.
All the late-breaking sessions will be held in the Clinical Science and Endovascular Theater, Exhibition Level, Hall C.
Links to all the late-breaking trial sessions in the TCT22 program.
Late-Breaking Clinical Science in Structural Heart Disease, Session I
In collaboration with The New England Journal of Medicine
Saturday, Sept. 17, 11 a.m. — 12:30 p.m. EDT
• PROTECTED TAVR Study: Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement. Presenter Samir R. Kapadia.
• CLASP II D Trial: A Randomized Comparison of Transcatheter Edge-to-Edge Repair Devices for Degenerative Mitral Regurgitation – Clinical Outcomes and Echo Findings. Presenters Konstantinos P. Koulogiannis and Scott Lim.
• TVT Registry: Transcatheter Edge-to-Edge Repair in Patients With Severe Mitral Regurgitation and Cardiogenic Shock. Presented by Mohamad A. Alkhouli.
• FRANCE-TAVI Trial: Results from Transcatheter Aortic Valve Replacement in Small Aortic Annuli. Presented by Walid Ben-Ali.
Late-Breaking Clinical Science in Structural Heart Disease, Session II
In collaboration with The European Heart Journal / EuroIntervention
Saturday, Sept. 17, 2 — 3:30 p.m. EDT
• Pathology of Self-Expanding Transcatheter Aortic Valve Failure and Hypo-Attenuated Leaflet Thickening (HALT). Presenter Yu Sato.
• Amulet IDE: 3-Year Outcomes from the Amplatzer Amulet Left Atrial Appendage Occluder Randomized Controlled Trial. Presenter Dhanunjaya Lakkireddy.
• Three-Year Outcomes of the Randomized SCOPE I Trial Comparing the Acurate Neo Versus the Sapien 3 Transcatheter Heart Valve System in Patients With Symptomatic Severe Aortic Stenosis. Presenter Jonas Lanz.
• EXPAND G4 Post Approval Study: Results of Contemporary Clinical and Echocardiographic Outcomes of 1,000+ Patients Treated with MitraClip G4. Presenters Jason H. Rogers and Ralph Stephan von Bardeleben.
• The PASCAL IID Registry: A Prospective Registry for Transcatheter Edge-to-Edge Repair in Prohibitive Risk Patients With Degenerative Mitral Regurgitation and Complex Mitral Valve Anatomy. Presenter Jörg Hausleiter.
• United Kingdom National Registry: Percutaneous or Surgical Management of Post-Infarction Ventricular Septal Defects. Presenter Joel Peter Giblett.
Late-Breaking Clinical Science in Vascular Disease and Hypertension, Session III
In collaboration with The Journal of the American Medical Association
Sunday, Sept. 18, 11 a.m. — 12:30 p.m. EDT
• RADIANCE II Trial: Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled Pivotal Trial. Presenter Ajay J. Kirtane.
• SYMPLICITY HTN-3 Trial: Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-year Follow-up. Presenter Deepak L. Bhatt.
• Pulmonary Artery Denervation for Pulmonary Arterial Hypertension: A Sham-Controlled Randomized Trial. Presenter Shao-Liang Chen.
• Flash FlowTriever Mechanical Thrombectomy Registry in Pulmonary Embolism: Outcomes for the Full U.S. Cohort. Presenter Catalin Toma.
• UNIVERSAL Trial: Ultrasound Guidance for Vascular Access for Cardiac Procedures: A Randomized Trial. Presenter Sanjit S. Jolly.
Late-Breaking Clinical Science Session in Structural Heart Disease, Session IV
In collaboration with The Journal of the American College of Cardiology
Sunday, Sept. 18, 2 — 3:30 p.m. EDT
• CONFIDENCE Registry: Valve Hemodynamics and 1-Year Survival Following Implantation of the Portico Valve in Experienced TAVI Centers. Presenter Helge Möllmann.
• Mediators of Improvement in TAVR Outcomes Over Time: Insights from the STS-ACC TVT Registry. Presenter Suzanne V. Arnold.
• Frequency and Safety of Bioprosthetic Valve Fracture in Patients Undergoing Valve in Valve TAVR for Failed Surgical Valves Using the Sapien 3/Ultra Valves: Insights From Real-World Data. Presenter Santiago Garcia.
• Increased Risk of Surgical Aortic Valve Replacement After Prior Transcatheter Versus Surgical Aortic Valve Replacement. Presenter Robert B. Hawkins.
• Results from the PARTNER Trials: Cardiac Damage and Quality of Life After Aortic Valve Replacement. Presenter Philippe Genereux.
• Intrepid Pilot Study: Mid-term Echocardiographic Outcomes Following Transapical Mitral Valve Replacement Updates. Presenter Renuka Jain.
Late-Breaking Clinical Science in Coronary Artery Disease, Session V
In collaboration with The Lancet
Monday, Sept. 19, 11: a.m. — 1 p.m. EDT
• BEST Trial: Everolimus-Eluting Stents or Bypass Surgery for Mutivessel Coronary Artery Disease: 10-Year Outcomes of Multicenter Randomized Controlled Trial. Presenter Jung-Min Ahn.
• Swedish Coronary Angiography and Angioplasty Registry: Survival after PCI or CABG for Left Main Coronary Disease. Presenter Elmir Omerovic.
• Randomized Controlled Trial Assessing The Value Of Computed Tomography Cardiac Angiography (CTCA) In Improving Patient Satisfaction And Reducing Contrast Load, Procedural Duration And Complications In Patients Who Had Previous Bypass Operation (CABG) Undergoing Invasive Coronary Angiography. Presenter Daniel A. Jones.
• FAME 3 Substudies: Clinical Outcomes Related to Anatomic vs. Functional Significance and Prognostic Value of Post-PCI FFR. Presenters Yuhei Kobayashi and Zsolt Piroth.
• Two-Year Outcomes of the FAVOR III China Trial: Angiographic Quantitative Flow Ratio-Guided Coronary Intervention. Presenter Lei Song.
Late-Breaking Clinical Science in Coronary Artery Disease, Session VI
In collaboration with Circulation
Monday, Sept. 19, 2 — 3:30 p.m. EDT
• Randomized, Double-Blind Trial of Routine Early Treatment with PCSK-9 inhibitor in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Presenter Shamir R. Mehta.
• RIVARAD Multicentric Randomized Trial: Prevention of Radial Artery Occlusion With Rivaroxaban After Transradial Coronary Procedures. Presenter Rania Hammami.
• EXpansion of Stents After Intravascular LithoTripsy Versus Conventional Predilatation in CALCified Coronary Arteries. Presenter Thomas Oomens.
• The COPS Randomized Trial: Cutting Balloon to Optimize Predilatation for Stent Implantation. Presenter Antonio Mangieri.
• TACTICS Registry: Impact of Underlying Causes of Acute Coronary Syndrome and 1-Year Outcomes After Percutaneous Coronary Intervention: Results From Optical Coherence Tomography Guided Primary Percutaneous Coronary Intervention Registry. Presenter Toshiro Shinke.
• SUGAR Trial: Two-Year Outcomes Of The Randomized Second-Generation Drug-Eluting Stents In Diabetes (SUGAR) Trial. Presenter Pablo Salinas.
Access the entire TCT 2022 program guide of sessions.
Related TCT 2022 News:
FDA clears Edwards Pascal device for transcatheter mitral valve repair
Other Late-breaking Cardiology Content:
Links to the ACC.22 late-breaking clinical trials
Links to the late-breaking studies at Heart Rhythm 2022
Links to all the SCAI 2022 late-breaking clinical research
Links to all the late-breaking structural heart studies at TVT 2022
VIDEO: TAVR durability outperforms surgical valves — Interview with Michael Reardon, MD
Key Interventional Cardiology Takeaways at ACC 2022
Key interventional cardiology takeaways from the SCAI 2022 conference
VIDEO: Pascal effective in transcatheter repair of tricuspid valve regurgitation — Interview with Adam Greenbaum, MD
Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: dfornell@innovatehealthcare.com